Monte Rosa Therapeutics Inc (GLUE) Stock Price, Quote & News

Latest News on GLUE

Jan 6, 2025, 7:00 AM EST - 12 days ago

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 7:00 AM EST - 5 weeks ago

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

Dec 11, 2024, 7:00 AM EST - 5 weeks ago

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Dec 11, 2024, 7:00 AM EST - 5 weeks ago

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Dec 5, 2024, 7:00 AM EST - 6 weeks ago

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Oct 28, 2024, 3:06 PM EDT - 2 months ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Aug 19, 2024, 7:00 AM EDT - 5 months ago

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 8, 2024, 8:36 AM EDT - 6 months ago

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Jun 27, 2024, 7:00 AM EDT - 7 months ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Jun 14, 2024, 8:45 AM EDT - 7 months ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

May 30, 2024, 7:00 AM EDT - 8 months ago

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 8 months ago

Monte Rosa Therapeutics Announces Leadership Team Promotions

May 21, 2024, 7:00 AM EDT - 8 months ago

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

May 16, 2024, 7:00 AM EDT - 8 months ago

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

May 15, 2024, 4:01 PM EDT - 8 months ago

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 9, 2024, 7:00 AM EDT - 9 months ago

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 4:01 PM EDT - 9 months ago

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

Mar 14, 2024, 7:00 AM EDT - 11 months ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 7:00 AM EDT - 11 months ago

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Jan 31, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Jan 8, 2024, 7:15 AM EST - 1 year ago

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

Jan 3, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 10:00 AM EST - 1 year ago

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Oct 31, 2023, 8:56 AM EDT - 1 year ago

Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value

Oct 26, 2023, 4:30 PM EDT - 1 year ago

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

Oct 17, 2023, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Oct 17, 2023, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

Aug 10, 2023, 7:15 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 26, 2023, 7:30 AM EDT - 1 year ago

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

May 30, 2023, 4:30 PM EDT - 1 year ago

Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

May 23, 2023, 7:30 AM EDT - 1 year ago

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

May 11, 2023, 7:30 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Apr 17, 2023, 4:30 PM EDT - 1 year ago

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

Mar 23, 2023, 7:30 AM EDT - 1 year ago

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 3, 2023, 7:30 AM EST - 2 years ago

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

Jan 9, 2023, 7:30 AM EST - 2 years ago

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

Jan 4, 2023, 7:30 AM EST - 2 years ago

Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 10, 2022, 7:30 AM EST - 2 years ago

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Nov 1, 2022, 7:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

Oct 31, 2022, 4:30 PM EDT - 2 years ago

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

Oct 20, 2022, 4:30 PM EDT - 2 years ago

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

Sep 6, 2022, 7:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader

Aug 11, 2022, 7:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

May 11, 2022, 7:30 AM EDT - 2 years ago

Market Cap	347.43M
Revenue (ttm)	0.00
Net Income (ttm)	-135.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	631,100
Avg Vol	1,337,732
Day's Range	N/A - N/A
Shares Out	61.44M
Stochastic %K	14%
Beta	1.47
Analysts	Strong Sell
Price Target	$16.00